In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 EMAIL TO FRIEND     |      PRINTER FRIENDLY     |    
          advertisement

Transplant May Treat Metabolic Disorders in Womb

Oct. 16 (HealthDay News) -- U.S. researchers are testing a new approach in cord-blood transplants to treat genetic metabolic disorders in babies while they're still in the womb.

The new method uses a small, select number of therapeutic stem cells that have been treated to speed and improve engraftment (acceptance of the transplant by the body), explained Dr. Joanne Kurtzberg, a professor of pediatrics and pathology and director of the pediatric blood and marrow transplant program at Duke University Medical Center in Durham, N.C.

She and her team are studying the new procedure in a pilot trial open to pregnant women at risk for having children with fatal metabolic disorders, including Krabbe disease, metachromatic leukodystrophy, Pelizaeus-Maerzbacher disease, Tay-Sachs disease and Sandoff disease.

If untreated, these metabolic disorders can lead to bone, brain and central nervous system problems, and early death, the study authors noted in a Duke news release.

Donor cells used in the study will be made by the biopharmaceutical company Aldagen, Inc, which is a partner in the trial.

In many cases, cord-blood transplants after birth have proven successful in treating inherited metabolic disorders. Transplant timing is critical, Kurtzberg stressed.

"The idea is to give the baby cord-blood stem cells from a healthy donor that have the potential to provide healthy genes that can replace the ones that aren't working properly in the baby's own cells," Kurtzberg said in the news release.

In general, the earlier the transplant, the more likely it will work. That means that performing the transplant before the baby is born is ideal, she explained.

During the procedure, donor cells are injected directly into the fetus's abdomen at 12 to 14 weeks' pregnancy. At birth, the baby will be tested to see if the donor cells are present, and if they're fixing the malfunctioning genes. If not, the baby would be eligible for conventional cord-blood stem cell transplant within a few weeks.


SOURCE: Duke Medicine, news release, Oct. 13, 2009

advertisement

Advice from Dr. Nancy Snyderman

Dr. Nancy Snyderman

Helpful tips and information on weight loss

Get answers from an expert
advertisement

YourTotalHealth      

Home  |  Health Centers  |  Health A-Z  |  Staying Healthy  |  Diet & Fitness  |  Woman & Family  |  Pregnancy  |  Community  |  

also on iVillage: Pregnancy & Parenting  |  Beauty & Style  |  Home & Garden  |  Food  |  Weddings  |  Love  |  Entertainment  |  NeverSayDiet

Terms of Service  |  Privacy Policy  |  Site Map  |  Newsletters  |  Feedback

Copyright (c) 2000-2009 iVillage Inc. All rights reserved. The information provided on this site is intended for your general knowledge only and is not a substitute for professional medical advice or treatment for specific medical conditions. You should not use this information to diagnose or treat a health problem or disease without consulting with a qualified healthcare provider. Please consult your healthcare provider with any questions or concerns you may have regarding your condition.